Loading
A phase 2 trial of osimertinib in lung cancer, run by Abbisko Therapeutics Co, Ltd, not yet recruiting.
A Phase 2 Study of ABSK043 Combined With Osimertinib is a phase 2, interventional study registered as NCT07710612 by Abbisko Therapeutics Co, Ltd, with a registry enrolment figure of 72 participants, started 2026-08-31 and due to reach its primary completion in 2029-12-31. Interventions recorded: ABSK043 in combination with Osimertinib. Conditions listed: Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive. Primary outcome: - Incidence of dose-limiting toxicity (DLT); Adverse events(AEs); Serious adverse events (SAEs). Lung eligibility wording from the registry: "NSCLC with a mixed histology is eligible, if adenocarcinoma is the predominant histology". Sites: China. No results are recorded here; the registry entry is the source.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), AstraZeneca and the tag lung-deep-dive.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), AstraZeneca and the tag lung-deep-dive.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.